The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review
Saved in:
Adams, A., et al., The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review. Substance Abuse Treatment, Prevention and Policy, nº. 56, 2023, p. 1-50.
Ref.
591185
Location:
SIIS Archivo (R.1834)
Palabras clave:
Tratamiento, Opiáceos, COVID
Tratamiento, Opiáceos, COVID
Abstract:
La pandemia de COVID-19 condujo a una relajación sin precedentes de las restricciones sobre las dosis para llevar a casa en el tratamiento con agonistas opiáceos (TAO). Se llevó a cabo una revisión sistemática de métodos mixtos para explorar el impacto de estos cambios en la eficacia de los programas y las experiencias de los clientes en el tratamiento con agonistas opiáceos.
La pandemia de COVID-19 condujo a una relajación sin precedentes de las restricciones sobre las dosis para llevar a casa en el tratamiento con agonistas opiáceos (TAO). Se llevó a cabo una revisión sistemática de métodos mixtos para explorar el impacto de estos cambios en la eficacia de los programas y las experiencias de los clientes en el tratamiento con agonistas opiáceos.
Similar Items: The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review
- Examining inequities in access to opioid agonist treatment (OAT) take-home doses (THD): A Canadian OAT guideline synthesis and systematic review
- Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT)
- Alcohol-related deaths during the Covid-19 pandemic
- Methadone-involved overdose deaths in the US before and after federal policy changes expanding take-home methadone doses from opioid treatment programs
- Examining the needs of family caregivers of people living with dementia in the community during the COVID-19 pandemic
- Harnessing telemedicine to deliver patient-centered opioid agonist treatment within a community-based harm reduction service: a mixed methods evaluation